[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100252049":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":23,"locations":33,"responsibleParty":51,"collaborators":53,"id":55,"slug":10,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":10,"maxAge":62,"enrollmentInfo":63,"targetDuration":66,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Associazione Italiana Ematologia Oncologia Pediatrica","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"patients NB with SCI",null,"Survival and late effects. Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse\u002Fprogression).",[13],"Other: survival and late effects",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"survival and late effects",[9],[19],{"name":20,"affiliation":21,"role":22},"Riccardo Haupt, MD","Istituto Giannina Gaslini Genova","PRINCIPAL_INVESTIGATOR",[24,29],{"name":20,"role":25,"phone":26,"phoneExt":27,"email":28},"CONTACT","01056363462","+39","riccardohaupt@ospedale-gaslini.ge.it",{"name":30,"role":25,"phone":31,"phoneExt":27,"email":32},"tiziana landi","051\u002F2144667","segreteria@aieop.org",[34],{"facility":35,"status":36,"city":37,"state":10,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Istituto Giannina Gaslini","RECRUITING","Genova","16147","Italy",{"type":41,"coordinates":42},"Point",[43,44],11.87211,45.21604,{"lat":44,"lon":43},[47,48],{"name":20,"role":25,"phone":26,"phoneExt":10,"email":28},{"name":49,"role":25,"phone":10,"phoneExt":10,"email":50},"Stefania Sorrentino","stefaniasorrentino@ospedale-gaslini.ge.it",{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[54],{"name":35,"class":6},"100252049",false,"NCT02559804","Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)","NB-SCI","Inclusion Criteria:\n\n* Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse\u002Fprogression)\n* No previous chemotherapy, except steroids, in the last 6 months\n* Age \\\u003C18 years\n* Minimal planned follow-up of 5 years\n* Parent\u002Fpatient written informed consent (Appendix 1(A,B,C))\n\nExclusion Criteria:\n\n* Invasion of intervertebral foramina only","ALL","18 Years",{"count":64,"type":65},150,"ESTIMATED","5 Years","OBSERVATIONAL","To describe the natural history of peripheral neuroblastic tumour presenting with SCI and evaluate the combined effects of different risk factors on the eventual neurologic and orthopaedic outcomes",[70],"Neuroblastic Tumors","2024-04-12",{"date":73,"type":74},"2024-04-15","ACTUAL",{"date":76,"type":10},"2014-05",{"date":78,"type":65},"2029-05",{"name":5,"class":6},1]